Summit Therapeutics sinks about 20% after FDA rejects lung cancer drug ivonescimab
Reuters (via 104.9 The Wolf) · · AI-summarised by FinFlash
Summit Therapeutics shares fell 19.9% to Negative read-across for PD-1/VEGF bispecific programs across big pharma and for Akeso; the first-line trial due later this year is the next catalyst. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context